Hosni was appointed CEO in 2021. The company operates four manufacturing sites, including a joint venture facility in Algeria, with products sold in 36 countries across the MEA region. In H1 2025, the company recorded $555.3 million in assets, and $227.6 million in revenues. In January 2024, it signed an agreement with the Local Content & Government Procurement Authority to become the preferred local supplier of Sitagliptin for government and institutional buyers starting in 2026. Hosni previously held leadership roles at Pfizer and GSK.